OMICS technologies in reproductive medicine: Assessment of quality of oocytes and embryos by unknown
Genes and Cells 2018 vol.13 N1, pages 35-41
OMICS technologies in reproductive medicine:
Assessment of quality of oocytes and embryos
Kazan Federal University, 420008, Kremlevskaya 18, Kazan, Russia
Abstract
© 2018 Human Stem Cell Institute. All rights reserved. One of the main factors of success of the
procedure  art  (assisted  reproductive  technology)  is  the  selection  of  the  most  high-quality
gametes for further manipulation and obtaining a viable embryo for implantation. The majority
of modern techniques based on morphokinetic predictors of quality (i. e. assessment of embryo
morphology and rate of division of the blastomeres), which allowed to achieve some success in
increasing  the  percentage  of  successful  pregnancies  and  reduce  the  number  of  multiple
pregnancies, but their accuracy is currently insufficient. Thus, the development of objective,
reliable,  fast  and  affordable  test  systems  to  determine  the  quality  of  oocytes  and  the
development potential  of  the embryo one of  the challenges of  reproductive medicine.  The
purpose of this review was to describe the advantages and limitations obecnych technologies,
the application of which will allow to deepen our understanding of the physiology of the embryo,
as well  as  set  criteria  for  non-invasive selection of  gametes and embryos.  In  this  regard,
recently in assisted reproduction are applied the studies of genomic, proteomic, transcript, and
metabolomic profiles of oocytes, granulosa and Cumulus cells, embryos, of conditioned media.
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